Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout

International Journal of Medical Sciences

Volumn 4, Issue 2, 2007, Pages 83-93

  Cammalleri, Lisa ^a   Malaguarnera, Mariano ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE   (Italy)

Author keywords

Acute renal failure; Allantoin; Allopurinol; Gout; Hyperuricemia; Rasburicase; Tumor lysis syndrome; Urate oxidase; Uric acid

Indexed keywords

ALLOPURINOL; ALUMINUM HYDROXIDE; AZATHIOPRINE; CHLORPROPAMIDE; CYCLOSPORIN; DICOUMAROL; FEBUXOSTAT; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; OXIPURINOL; POLYETHYLENE GLYCOL URICASE; RASBURICASE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID; URICOZYME;

ABDOMINAL PAIN; ALBUMINURIA; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ARTHRALGIA; BRONCHOSPASM; CLINICAL TRIAL; CONVULSION; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXFOLIATIVE DERMATITIS; FEBRILE NEUTROPENIA; FEVER; GOUT; HEADACHE; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; HYPOXEMIA; HYPOXIA; INJECTION SITE INDURATION; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER TOXICITY; METHEMOGLOBINEMIA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC VASCULITIS; TUMOR LYSIS SYNDROME; URTICARIA;

EID: 33947257299     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.4.83     Document Type: Review

References (70)

1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127:3-11.
2. Choi HK, Mount DB, Reginato AM. American College of Physicians, American Physiological Society Pathogenesis of gout. Ann Intern Med. 2005; 143: 499-516.
3. Campion EW, Glynn RJ, Delabry LO. Asyntomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med.1987; 82: 421-426
4. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asyntomatic hyperuricemic men in a prospective study. Journal of Rheumatology. 2000; 27:1501-1505.
5. Leusmann DB. A classification of urinary calculi with respect to their composition and micromorphology. Scand J Urol. 1991;25:141-50.
6. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med. 2004; 116:546-554.
7. Kang DH, Nakagawa T, Feng L, et al. A Role for Uric Acid in the Progression of Renal Disease. J Am Soc Nephrol. 2002;13:2888-2897
8. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Medical hypotheses. 2001;56:95-100
9. Kelly SJ, Delnomdedieu M, Oliverio MI. Diabetes Insipidus in Uricase-Deficient Mice: A Model for Evaluating Therapy with Poly(Ethylene Glycol)-Modified Uricase. J Am Soc Nephrol. 2001;12:1001-1009.
10. Navolanic PM, Pui CH, Larson RA, et al. Elitek - rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003;17:499-514.
11. Leplatois P, Le Douarin B, Loison G. High-level production of a peroxisomal enzyme: Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae. Gene. 1992; 122:139-145.
12. Bayol A, Capdevielle J, Malazzi P, et al. Modification of a reactive cysteine explains differences between rasburicase and Uricozyme™, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem. 2002;36:21-31.
13. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19:697-704
14. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumour lysis. Blood. 2001; 97:2998-3003.
15. Chua CC, Greenberg ML, Viau AT, et al. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non- Hodgkin lymphoma. Ann Intern Med. 1988; 109:114-117
16. Ganson NJ, Kelly SJ, Scarlett E. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2005; 8:R12
17. Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005; 18: 275-279.
18. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients final results of a multicenter compassionate use trial. Leukemia. 2005; 19:34-38.
19. Oldfield V, Perry CM. Rasburicase. A review of its use in the management of anticancer therapy-induced hyperuricemia. Drugs. 2006; 66:529-545.
20. Hummel M, Buchheidt D, Reiter S, et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukaemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol. 2005; 75:518-521.
21. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res. 2005; 29:463-465.
22. Hutcherson DA, Gammon DC, Bhatt MS, et al. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacother. 2006; 26:242-247
23. McDonnel AM, Lenz KL, Frei-Lahr DA, et al. Single-dose rasburicase 6mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006; 26:806-812.
24. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006; 37:997-1001.
25. Tarella C, Bono D, Zanni M, et al. Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia. Contrib Nephrol. 2005;147:93-104.
26. Jeha S, Pui CH. Recombinant urate oxidase (Rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol. 2005;147:69-79.
27. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Annals of Oncology. 2002; 13: 789-795
28. Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia. Semin Hematol. 2001; 38:9-12.
29. Leach M, Parsons RM, Reilly JT, Winfield DA. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol. 1998; 20:169-172.
30. Jankovic M, Zurlo MG, Rossi E, et al. Urate-oxidase as hypouricemic agent in a case of acute tumour lysis syndrome. Am J Pediatr Hematol Oncol. 1985; 7: 202-204.
31. Riccio B, Mato A, Olson EM, Berns JS, Luger S. Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther. 2006;5:1614-7
32. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006; 3:438-447.
33. Crittenden DR, Ackerman GL. Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med. 1977;137:97-99.
34. Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol. 1993; 21:521-524.
35. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors-a case report and rewiew of the literature. Cancer Chemother and Pharmacol. 2003; 51:187-192.
36. Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (Rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11:249-257.
37. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-1509.
38. Macfarlane RJ, McCully BJ, Ferandez CV. Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. Pediatr Nephrol. 2004; 19:924-927.
39. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol. 2001; 38(4 Suppl 10):13-21.
40. Vora A, Bhutani M, Sharma A et al. Severe tumor lysis sindrome during treatment with STI 571 in a patient with chronic myelogenous leucemia accelerated phase. Ann Oncol. 2002; 13:1833-1834.
41. Pession A, Barbieri E. Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib Nephrol. 2005;147:80-92.
42. Coiffier B, Riouffol C. Management of tumor lysis syndrome in adults. Expert Rev Anticancer Ther. 2007; 7:233-9
43. Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol. 2006; 2:338-342.
44. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002; 29:2403-2406.
45. Moolenburgh JD, Reinders MK, Jansen TLThA. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol. 2006; 25:749-752.
46. Baraf H, Kim S, Matsumoto AK, et al. Resolution of tophi with intravenous Peg-uricase in refractory gout. Arthritis Rheum. 2005; 52:S105.
47. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005; 20:431-433.
48. Rozenberg S, Roche B, Dorent R, et al. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed. 1995;62:392-394.
49. Wortmann RL . Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol. 2005; 17:319-324
50. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine. 2004; 71:481-485.
51. 2-generating peroxisomal urate oxidase. Cancer Res. 1996 ; 56: 4846-4852.
52. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase, in subjects with renal impairment. Am J Ther. 2005;12: 22-34.
53. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003; 98:1048-1054.
54. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997; 11:1813-1816
55. Wolf G, Hegewisch - Becker S, Hossfeld DK, et al. Hyperuricaemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy?. Am J Kidney Dis. 1999; 34: E20
56. Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother Pharmacol. 1982;8:93-98.
57. Jaeger H, Russmann D, Rasper J, Blome J. Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations. Arzneimittelforschung. 1982; 32:438-443
58. Schlesinger N. Management of acute and chronic gouty arthritis - Present state of the art. Drugs 2004; 64:2399-2416
59. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999. 48:501-509
60. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones - a rare complication of allopurinol therapy. New Engl J Med. 1969; 280:426-427
61. Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med. 1965; 62:639-647
62. Moreau D. Pharmacological treatment of acute renal failure in intensive care unit patients. Contrib Nephrol. 2005; 147:161-173.
63. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome. A review. Ann Pharmacother. 1993; 27:337-343.
64. Hsu HH, Chan YL, Hung CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure; clinical feauture and therapeutic approach. J Nephrol. 2004; 17: 50-56.
65. Agha-Razii M, Amyot SL, Pichette V, et al. Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol. 2000; 54:59-63.
66. Coiffier B, Mounier N, Bologna S et el. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des lymphomas de l'Adulte Trial in Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003; 21:4402-4406.
67. Stapleton FB, Strother DR, Roy S 3rd, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988; 82:863-869.
68. Bordoni V, Cal MD, Rassu M, et al. Protective Effect of Urate Oxidase on Uric Acid Induced-Monocyte Apoptosis. Curr Drug Discov Technol. 2005; 2:29-36
69. Pui CH. Rasburicase: A potent uricolytic agent. Expert Opin Pharmacother. 2002; 3:433-442.
70. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother. 2005; 39: 1932-5